All In Biotech

Drug Trial Radar · NCT02098473

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis

Last checked: Nov 19, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Aug 31, 2014

Primary completion

Feb 17, 2016

Study completion Jan 30, 2017

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.

Conditions

  • Eosinophilic Esophagitis

Interventions

  • RPC4046Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Eosinophil CountTime frame: Week 16

Locations

30 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Arizona

    Scottsdale, Arizona

  • Desert Sun Clinical Research, LLC

    Tucson, Arizona

  • Alliance Clinical Research

    Oceanside, California

  • Precision Research Institute, LLC

    San Diego, California

  • University of Colorado School of Medicine

    Aurora, Colorado

  • Connecticut Clinical Research Foundation

    Bristol, Connecticut

  • University of Florida

    Gainesville, Florida

  • Borland-Groover Clinic

    Jacksonville, Florida

  • Children's Center for Digestive Healthcare

    Atlanta, Georgia

  • Grand Teton Research Group

    Idaho Falls, Idaho

  • Northwestern University-Feinberg School of Medicine

    Chicago, Illinois

  • Southwest Gastroenterology

    Oak Lawn, Illinois

  • Indiana University

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Gastroenterology and Hepatology Service Walter Reed National Military Medical Center

    Bethesda, Maryland

  • Metropolitan Gastroenterology Group Chevy Chase Clinical Research

    Chevy Chase, Maryland

  • West Michigan Clinical Research Center Gastroenterology Associates of Western Michigan

    Wyoming, Michigan

  • Minnesota Gastroenterology

    Plymouth, Minnesota

  • GI Associates and Endoscopy Center-GI Clinical Research Department

    Flowood, Mississippi

  • Darthmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Asheville Gastroenterology Associates, PA

    Asheville, North Carolina

  • University of North Carolina

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Great Lakes Gastroenterology Research

    Mentor, Ohio

  • University of Pennsylvania Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Vanderbilt University

    Nashville, Tennessee

  • University of Utah Division of Gastroenterology

    Salt Lake City, Utah

  • Gastrointestinal Research Group, University of Calgary Health

    Calgary, Alberta, Canada

  • Centre Hospitalier Universitaire Vaudois (CHUV)

    Lausanne, Switzerland

  • Swiss EoE Clinic

    Olten, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.